Cited by 107Epigenetics and DNA MethylationCervical Cancer and HPV ResearchEndometrial and Cervical Cancer Treatments

Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons.

Open access
Bakkum-Gamez, Jamie N., Wentzensen, Nicolas, Maurer, Matthew J., Hawthorne, Kieran M., Voss, Jesse S., Kroneman, Trynda N., Famuyide, Abimbola O., Clayton, Amy C. +10 more·2015·Gynecologic Oncology

Abstract

Objective We demonstrate the feasibility of detecting EC by combining minimally-invasive specimen collection techniques with sensitive molecular testing.Methods Prior to hysterectomy for EC or benign indications, women collected vaginal pool samples with intravaginal tampons and underwent endometrial brushing. Specimens underwent pyrosequencing for DNA methylation of genes reported to be hypermethylated in gynecologic cancers and recently identified markers discovered by profiling over 200 ECs. Methylation was evaluated individually across CpGs and averaged across genes. Differences between EC and benign endometrium (BE) were assessed using two-sample t-tests and area under the curve (AUC).Results Thirty-eight ECs and 28 BEs were included. We evaluated 97 CpGs within 12 genes, including previously reported markers (RASSF1, HSP2A, HOXA9, CDH13, HAAO, and GTF2A1) and those identified in discovery work (ASCL2, HTR1B, NPY, HS3ST2, MME, ADCYAP1, and additional CDH13 CpG sites). Mean methylation was higher in tampon specimens from EC v. BE for 9 of 12 genes (ADCYAP1, ASCL2, CDH13, HS3ST2, HTR1B, MME, HAAO, HOXA9, and RASSF1) (all p<0.05). Among these genes, relative hypermethylation was observed in EC v. BE across CpGs. Endometrial brush and tampon results were similar. Within tampon specimens, AUC was highest for HTR1B (0.82), RASSF1 (0.75), and HOXA9 (0.74). This is the first report of HOXA9 hypermethylation in EC.Conclusion DNA hypermethylation in EC tissues can also be identified in vaginal pool DNA collected via intravaginal tampon. Identification of additional EC biomarkers and refined collection methods are needed to develop an early detection tool for EC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ygyno.2015.01.552

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Interest has grown in using biomarkers such as DNA methylation to improve early detection of endometrial cancer.

    “Interest has increased in the use of biomarkers, such as DNA methylation, to i mprove early detection of endometrial cancer. 31,32,170,171”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

3 of the 57 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Bakkum-Gamez, J. N., Wentzensen, N., Maurer, M. J., Hawthorne, K. M., Voss, J. S., Kroneman, T. N., Famuyide, A. O., Clayton, A. C., Halling, K. C., Kerr, S. E., Cliby, W. A., Dowdy, S. C., Kipp, B. R., Mariani, A., Oberg, A. L., Podratz, K. C., Shridhar, V., & Sherman, M. E.
Affiliations
  • Mayo Clinic (US)
  • National Cancer Institute (US)
Corresponding author
Bakkum-Gamez, Jamie N.
Venue
Gynecologic Oncology
Publisher
Elsevier BV
Published
2015-04
Volume
137
Issue
1
Pages
14-22
ISSN
0090-8258 (ISSN-L)
OpenAlex
W2147798100
Cited by
107
References
57
Citations by year
2026: 12 · 2025: 8 · 2024: 11 · 2023: 11 · 2022: 9 · 2021: 15 · 2020: 11 · 2019: 12 · 2018: 6 · 2017: 3 · 2016: 6 · 2015: 3
FWCI
2.59
Type
journal article
Language
en
Open access
Locations
  • Gynecologic Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
NCI Cancer Center Support (P30 CA 15083)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
  • Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
Keywords
endometrial cancer, DNA methylation, hypermethylation, vaginal tampons, tumor markers, early cancer detection, HOXA9, RASSF1, 5-HT1B receptor, CpG sites
MeSH terms
Aged, DNA, Neoplasm, Female, Humans, Middle Aged, Neoplasm Staging, Pilot Projects, Biomarkers, Tumor, Vagina, Case-Control Studies, Endometrial Neoplasms, CpG Islands, DNA Methylation, Menstrual Hygiene Products

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review